Anticancer and Immunostimulatory Activity by Conjugate of Paclitaxel and Non-toxic Derivative of LPS for Combined Chemo-immunotherapy

Roy, Aniruddha; Chandra, S.; Mamilapally, Swapna; Upadhyay, Pramod; Bhaskar, Sangeeta

doi:10.1007/s11095-012-0756-y

Cited by 30 publications

(22 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These conjugates self-assemble into ~200 nm NPs which upon intravenous administration increase the amount of phenotypically mature macrophages and activated CTLs into the tumor. More importantly, these conjugate NPs resulted in an improved therapeutic outcome compared to each treatment moiety alone [143]. Similar observations could be made when paclitaxel was co-encapsulated with SP-LPS into PLGA NPs [144].…”

Section: Chemo-immunotherapysupporting

confidence: 63%

Nanoparticle design to induce tumor immunity and challenge the suppressive tumor microenvironment

et al. 2014

View full text Add to dashboard Cite

Over the years research in the field of cancer immunotherapy has flourished, bringing about crucial breakthroughs, but at the same time revealing new and important pathways of immune suppression that put a break on the success of cancer immunotherapy. This review focuses on how nano-and micromaterials can be used to induce antitumor immune responses and what their role in overcoming immune suppression could be. It is now beyond question that this requires elegantly designed particles that can reach their target cells, deliver antigenic cargo and most importantly immune stimulants in order to provoke and sustain antitumor immunity.3

show abstract

Section: Chemo-immunotherapysupporting

confidence: 63%

Nanoparticle design to induce tumor immunity and challenge the suppressive tumor microenvironment

et al. 2014

View full text Add to dashboard Cite

show abstract

“…[79] Instead, they conjugated PTX with SP-LPS,w hich subsequently self-assembled into aN P. These NPs showed higher in vivo antitumor activity and ah igher percentage of activated immune cells in the TME than the Taxol-treated group. [80] They also increased the loading of TLR-4 agonist from 20 %to65% by replacing SP-LPS with the similar P-LPS.T he higher P-LPS loading showed improved synergy with PTX when co-encapsulated into PLGA NPs,l eading to significant reduction in tumor growth compared with either stand-alone modality.F low cytometric analysis of tumor-infiltrating immune cells indicated high infiltration and activation of APCs and Tcells (CD4 + and CD8 + ), correlating to the enhanced survival of mice. [81] Similarly,S eth et al demonstrated the synergy between PTX and aT LR-7 agonist for treatment of B16F10 melanoma by using poly(g-glutamic acid) to co-deliver PTX and imiquimod.…”

Section: Chemotherapeutic Drugsmentioning

confidence: 99%

Nanoparticle‐Mediated Immunogenic Cell Death Enables and Potentiates Cancer Immunotherapy

2018

View full text Add to dashboard Cite

Cancer immunotherapies that train or stimulate the inherent immunological systems to recognize, attack, and eradicate tumor cells with minimal damage to healthy cells have demonstrated promising clinical responses in recent years. However, most of these immunotherapeutic strategies only benefit a small subset of patients and cause systemic autoimmune side effects in some patients. Immunogenic cell death (ICD)-inducing modalities not only directly kill cancer cells but also induce antitumor immune responses against a broad spectrum of solid tumors. Such strategies for generating vaccine-like functions could be used to stimulate a "cold" tumor microenvironment to become an immunogenic, "hot" tumor microenvironment, working in synergy with immunotherapies to increase patient response rates and lead to successful treatment outcomes. This Minireview will focus on nanoparticle-based treatment modalities that can induce and enhance ICD to potentiate cancer immunotherapy.

show abstract

“…Another study used a sequential administration of hyaluronic acid-paclitaxel complex followed by two types of PLGA nanoparticles loaded respectively with CpG-ODN and IL-10 siRNA also showing effective and synergistic results [32]. Other studies in a mouse model successfully used instead simultaneous co-delivery of chemotherapeutic drugs and immunomodulatory agents loaded in the same nanoparticle (Table 1) [33, 34]. …”

Section: Immunomodulatory Drug Deliverymentioning

confidence: 99%

The era of bioengineering: how will this affect the next generation of cancer immunotherapy?

et al. 2017

View full text Add to dashboard Cite

BackgroundImmunotherapy consists of activating the patient’s immune system to fight cancer and has the great potential of preventing future relapses thanks to immunological memory. A great variety of strategies have emerged to harness the immune system against tumors, from the administration of immunomodulatory agents that activate immune cells, to therapeutic vaccines or infusion of previously activated cancer-specific T cells. However, despite great recent progress many difficulties still remain, which prevent the widespread use of immunotherapy. Some of these limitations include: systemic toxicity, weak immune cellular responses or persistence over time and most ultimately costly and time-consuming procedures.Main bodySynthetic and natural biomaterials hold great potential to address these hurdles providing biocompatible systems capable of targeted local delivery, co-delivery, and controlled and/or sustained release. In this review we discuss some of the bioengineered solutions and approaches developed so far and how biomaterials can be further implemented to help and shape the future of cancer immunotherapy.ConclusionThe bioengineering strategies here presented constitute a powerful toolkit to develop safe and successful novel cancer immunotherapies.

show abstract

Anticancer and Immunostimulatory Activity by Conjugate of Paclitaxel and Non-toxic Derivative of LPS for Combined Chemo-immunotherapy

Abstract: This conjugate is a potential chemo-immunotherapeutic compound for the treatment of cancer with advantages over present day chemotherapy with Taxol in terms of higher anticancer activity, less toxicity and ease of delivery.

Cited by 30 publications

References 43 publications

Nanoparticle design to induce tumor immunity and challenge the suppressive tumor microenvironment

Nanoparticle design to induce tumor immunity and challenge the suppressive tumor microenvironment

Nanoparticle‐Mediated Immunogenic Cell Death Enables and Potentiates Cancer Immunotherapy

The era of bioengineering: how will this affect the next generation of cancer immunotherapy?

Contact Info

Product

Resources

About